Related Experiment Videos

Atorvastatin protects cardiomyocytes against OGD/Rinduced apoptosis by inhibiting miR199a5p

Yong Li1, Ting Jiang2, Xingli Fu3

  • 1Department of Cardiology, The Affiliated Wujin Hospital of Jiangsu University, Changzhou, Jiangsu 213017, P.R. China.

Insights

Atorvastatin protects heart cells from injury by increasing glycogen synthase kinase-3β (GSK-3β) expression. This occurs through inhibiting microRNA-199a-5p, offering a potential therapeutic strategy for myocardial ischemia/reperfusion injury.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Myocardial ischemia/reperfusion (I/R) injury poses a significant clinical challenge.
  • Cardiomyocyte protection strategies are crucial for managing heart conditions.
  • Understanding the molecular mechanisms of drug-induced cardioprotection is essential.

Purpose of the Study:

  • To evaluate the cardioprotective effects of atorvastatin against I/R injury in cardiomyocytes.
  • To elucidate the underlying molecular mechanisms involving GSK-3β and miR-199a-5p.
  • To assess the direct cytotoxic effects of oxygen-glucose deprivation/reperfusion (OGD/R) on cardiomyocytes.

Main Methods:

  • Utilized oxygen-glucose deprivation/reperfusion (OGD/R) model in cardiomyocytes.
  • Assessed atorvastatin's effects on cell viability.
  • Quantified gene and protein expression of GSK-3β and miR-199a-5p using RT-qPCR, western blot, and immunohistochemistry.

Main Results:

  • Atorvastatin pretreatment significantly improved cardiomyocyte viability after OGD/R.
  • Atorvastatin increased both mRNA and protein levels of GSK-3β.
  • Atorvastatin upregulated miR-199a-5p expression, which in turn modulated GSK-3β levels.

Conclusions:

  • Atorvastatin exhibits protective effects against I/R injury in cardiomyocytes.
  • The mechanism involves atorvastatin increasing GSK-3β expression.
  • This increase is mediated by the inhibition of miR-199a-5p, highlighting a novel therapeutic pathway.

Related Concept Videos